Luo PH - Search Results

1

The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis.

Mo DC, Huang JF, Lin P, Huang SX, Wang HL, Luo PH, Liang XJ. Mo DC, et al. Among authors: luo ph. Sci Rep. 2024 Oct 31;14(1):26200. doi: 10.1038/s41598-024-78159-y. Sci Rep. 2024. PMID: 39482343 Free PMC article.

2

Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.

Mo DC, Luo PH, Huang SX, Wang HL, Huang JF. Mo DC, et al. Among authors: luo ph. Int Immunopharmacol. 2021 Feb;91:107281. doi: 10.1016/j.intimp.2020.107281. Epub 2020 Dec 16. Int Immunopharmacol. 2021. PMID: 33338862

3

The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.

Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. Mo DC, et al. Among authors: luo ph. Int Immunopharmacol. 2021 Jul;96:107594. doi: 10.1016/j.intimp.2021.107594. Epub 2021 Mar 30. Int Immunopharmacol. 2021. PMID: 33798808 Review.

4

Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials.

Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. Mo DC, et al. Among authors: luo ph. Clin Immunol. 2021 Nov;232:108876. doi: 10.1016/j.clim.2021.108876. Epub 2021 Nov 2. Clin Immunol. 2021. PMID: 34740840 Review.

5

The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis.

Meng LF, Huang JF, Luo PH, Huang SX, Wang HL. Meng LF, et al. Among authors: luo ph. Invest New Drugs. 2022 Aug;40(4):810-817. doi: 10.1007/s10637-022-01232-8. Epub 2022 Apr 12. Invest New Drugs. 2022. PMID: 35412172 Review.

6

PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.

Mo DC, Huang JF, Luo PH, Chen L, Zou B, Wang HL. Mo DC, et al. Among authors: luo ph. Eur Arch Otorhinolaryngol. 2023 Jan;280(1):1-9. doi: 10.1007/s00405-022-07571-9. Epub 2022 Jul 30. Eur Arch Otorhinolaryngol. 2023. PMID: 35907001 Review.

7

Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: A meta-analysis of randomized controlled trials.

Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. Mo DC, et al. Among authors: luo ph. Medicine (Baltimore). 2022 Sep 23;101(38):e30830. doi: 10.1097/MD.0000000000030830. Medicine (Baltimore). 2022. PMID: 36197237 Free PMC article.

8

Low-Dose Immunotherapy Plus Triple Metronomic Chemotherapy for Head and Neck Cancer.

Mo DC, Huang JF, Luo PH. Mo DC, et al. Among authors: luo ph. J Clin Oncol. 2023 Mar 20;41(9):1790. doi: 10.1200/JCO.22.02398. Epub 2023 Jan 20. J Clin Oncol. 2023. PMID: 36669141 No abstract available.

9

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis.

Feng YN, Xie GY, Xiao L, Mo DC, Huang JF, Luo PH, Liang XJ. Feng YN, et al. Among authors: luo ph. Front Immunol. 2023 Jun 19;14:1196793. doi: 10.3389/fimmu.2023.1196793. eCollection 2023. Front Immunol. 2023. PMID: 37404816 Free PMC article.

10

Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab.

Luo PH, Mo DC, Wang HL, Liang XJ, Huang JF. Luo PH, et al. J Clin Oncol. 2024 May 1;42(13):1596. doi: 10.1200/JCO.23.02479. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452320 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters